Skip to content

Disc Medicine IRON Other income, net (Note 6)

Other income, net (Note 6) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$32M+90.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$53K-35.4%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$119K-90.5%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$91K-117%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's other income, net (note 6)?
Disc Medicine (IRON) reported other income, net (note 6) of $22K in Q1 2026.
How has Disc Medicine's other income, net (note 6) changed year-over-year?
Disc Medicine's other income, net (note 6) increased by 833.3% year-over-year, from -$3K to $22K.
What is the long-term trend for Disc Medicine's other income, net (note 6)?
Over 3 years (2021 to 2025), Disc Medicine's other income, net (note 6) has grown at a 53.5% compound annual growth rate (CAGR), from -$13K to $47K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.